Max Mendez Lopez
Medizinische Onkologie und Hämatologie · Dept. I
Targeting des Immunoproteasoms in vivo
Aug 1, 2023Proteasome sind vielversprechende Angriffspunkte für Medikamente bei Krebserkrankungen. Mehrere Proteasom-Inhibitoren werden bereits klinisch zur Behandlung des multiplen Myeloms (MM) eingesetzt. Aktuelle in der Klinik eingesetzte Proteasom-Inhibitor...
Fundamental Research - Aug 1, 2023 - Dec 31, 2023
Automatically Closed
Project leader: Driessen Christoph
Members: Mendez Lopez Max, Besse Lenka
Revealing molecular basis of cardiotoxicity of carfilzomib towards its safer use in the patients with multiple myeloma
Mar 1, 2020
Fundamental Research - Mar 1, 2020 - Feb 28, 2021
Automatically Closed
Project leader: Besse Lenka
Members: Mendez Lopez Max
Identifying and targeting the “Achilles’ heel” in proteasome inhibitor-resistant multiple myeloma
Oct 1, 2018The proposal aims at understanding the biology of proteasome inhibitor (PI)-refractory multiple myeloma (MM), in particular the specific vulnerabilities of PI-refractory MM, or so called “Achilles’ heel”, towards development of novel treatment option...
Fundamental Research - Oct 1, 2018 - Dec 31, 2021
Automatically Closed
Project leader: Driessen Christoph
Members: Besse Andrej, Kraus Marianne, Besse Lenka, Mendez Lopez Max
Preclinical investigation of cardiotoxicity as a clinically important side effect of proteasome inhibitor-based therapy
Jul 1, 2017Carfilzomib is the recently approved second generation proteasome inhibitor for multiple myeloma therapy. Carfilzomib has superior clinical activity than the first generation drug, bortezomib, putatively due to less off-target activity and an altered...
Fundamental Research - Jul 1, 2017 - Jun 30, 2018
Automatically Closed
Project leader: Besse Lenka
Members: Mendez Lopez Max